BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $200 million of its common stock and, in lieu of common stock, to offer and sell to certain investors…
